For example, resistance to EGFR-inhibitors due to compensatory MAPK, PI3K/ATK and STAT pathway activation [90] or co-occurring alterations in CTNNB1 and PIK3CA in lung cancer [91]. This evidence concerns the gene PIK3CA and lung carcinoma.